Ropanicant is under clinical development by Suven Life Sciences and currently in Phase I for Major Depressive Disorder. According to GlobalData, Phase I drugs for Major Depressive Disorder have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ropanicant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ropanicant overview

SUVN-911 is under development for the treatment of major depressive disorder (MDD). The drug candidate is administered through oral route in the form of tablet.The drug candidate acts by targeting nAChR alpha-4 beta-2.

Suven Life Sciences overview

Suven Life Sciences (Suven), formerly Suven Pharmaceuticals, provides drug discovery and development support services. The company offers research services specializing in drug metabolism and pharmacokinetics; CNS pharmacology including behavioral pharmacology, microdialysis, receptor occupancy and electrophysiology; toxicology and safety pharmacology; bioanalysis, synthetic, medicinal and analytical chemistry; in-vitro assay development and screening; and NCE formulations. Its product pipeline includes Masupirdine, Samelisant, Usmarapride, Ropanicant, SUVN-M8036 and SUVN-D1044. Suven’s therapeutic areas include alzheimer’s diseases, neuropsychiatric, narcolepsy, cognitive disorders, depressive disorders, psychiatric disorders, and gastro-intestinal disorders. The company operates its offices in India. Suven is headquartered in Hyderabad, Telangana, India.

For a complete picture of Ropanicant’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.